Stock COR CENCORA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Cencora, Inc.

Equities

COR

US03073E1055

Medical Equipment, Supplies & Distribution

Market Closed - Nyse
Other stock markets
 04:00:02 2024-05-31 pm EDT 		5-day change 1st Jan Change
226.6 USD +2.74% Intraday chart for Cencora, Inc. +3.51% +10.32%
May. 30 Transcript : Cencora, Inc. Presents at 2024 Leerink Partners Healthcare Crossroads Conference, May-30-2024 09:20 AM
May. 29 Baird Adjusts Price Target on Cencora to $280 From $277 MT

Valuation

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 17,151 19,785 24,820 28,048 36,148 44,618 - -
Enterprise Value (EV) 1 17,950 19,307 28,957 30,363 38,343 45,854 44,196 41,031
P/E ratio 20.4 x -5.82 x 16.2 x 16.8 x 21.1 x 22.1 x 18.9 x 16.7 x
Yield 1.94% 1.71% 1.49% 1.36% - 0.91% 0.93% 0.98%
Capitalization / Revenue 0.1 x 0.1 x 0.12 x 0.12 x 0.14 x 0.15 x 0.14 x 0.14 x
EV / Revenue 0.1 x 0.1 x 0.14 x 0.13 x 0.15 x 0.16 x 0.14 x 0.12 x
EV / EBITDA 7.63 x 7.77 x 9.73 x 8.55 x 10.4 x 11.4 x 10.2 x 8.91 x
EV / FCF 8.83 x 10.5 x 13 x 13.8 x 11.1 x 18.1 x 15.4 x 12.8 x
FCF Yield 11.3% 9.52% 7.7% 7.27% 9.01% 5.53% 6.49% 7.8%
Price to Book 5.91 x -19.4 x 111 x 401 x - 28.7 x 15.1 x 9.26 x
Nbr of stocks (in thousands) 208,326 204,142 207,787 207,258 200,854 196,929 - -
Reference price 2 82.33 96.92 119.4 135.3 180.0 226.6 226.6 226.6
Announcement Date 11/7/19 11/5/20 11/4/21 11/3/22 11/2/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 179,589 189,894 213,989 238,587 262,173 290,308 310,208 328,837
EBITDA 1 2,354 2,485 2,977 3,553 3,702 4,034 4,325 4,607
EBIT 1 2,051 2,204 2,648 3,163 3,289 3,641 3,882 4,124
Operating Margin 1.14% 1.16% 1.24% 1.33% 1.25% 1.25% 1.25% 1.25%
Earnings before Tax (EBT) 1 967.1 -5,294 2,222 2,183 2,161 2,465 2,709 3,002
Net income 1 855.4 -3,409 1,540 1,699 1,745 2,012 2,325 2,575
Net margin 0.48% -1.8% 0.72% 0.71% 0.67% 0.69% 0.75% 0.78%
EPS 2 4.040 -16.65 7.390 8.040 8.530 10.25 11.96 13.57
Free Cash Flow 1 2,034 1,837 2,228 2,207 3,453 2,534 2,870 3,200
FCF margin 1.13% 0.97% 1.04% 0.92% 1.32% 0.87% 0.93% 0.97%
FCF Conversion (EBITDA) 86.4% 73.94% 74.85% 62.11% 93.27% 62.81% 66.35% 69.45%
FCF Conversion (Net income) 237.77% - 144.71% 129.9% 197.85% 125.95% 123.46% 124.29%
Dividend per Share 2 1.600 1.660 1.780 1.840 - 2.064 2.114 2.220
Announcement Date 11/7/19 11/5/20 11/4/21 11/3/22 11/2/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: September 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3
Net sales 1 59,629 57,719 60,065 61,174 62,847 63,457 66,947 68,922 72,253 68,414 73,568 75,768 76,632 73,031 78,732
EBITDA 1 845.6 1,014 853.9 839.4 833.8 1,033 927.4 907.3 990.6 1,141 972.6 960.2 1,044 1,196 1,041
EBIT 1 749.1 916.6 756.2 741.5 733.7 932.1 822.3 801 885.7 1,034 868.8 852.2 935.4 1,113 931.7
Operating Margin 1.26% 1.59% 1.26% 1.21% 1.17% 1.47% 1.23% 1.16% 1.23% 1.51% 1.18% 1.12% 1.22% 1.52% 1.18%
Earnings before Tax (EBT) 1 596.2 728.2 476.3 382.3 593.5 512.1 608.8 446.4 783.4 467.1 602.5 591.7 649.1 826.5 684.2
Net income 1 449.1 548 407 294.7 479.7 435.4 479.6 350.6 601.5 420.8 493.9 469.9 569.3 705.6 574.6
Net margin 0.75% 0.95% 0.68% 0.48% 0.76% 0.69% 0.72% 0.51% 0.83% 0.62% 0.67% 0.62% 0.74% 0.97% 0.73%
EPS 2 2.130 2.590 1.920 1.400 2.330 2.130 2.350 1.720 2.980 2.090 2.587 2.552 2.917 3.575 3.015
Dividend per Share 2 0.4600 0.4600 0.4600 0.4600 0.4850 0.4850 0.4850 - - - 0.5173 0.5173 0.5205 0.5205 0.5205
Announcement Date 2/2/22 5/4/22 8/3/22 11/3/22 2/1/23 5/2/23 8/2/23 11/2/23 1/31/24 5/1/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 799 - 4,137 2,315 2,195 1,235 - -
Net Cash position 1 - 478 - - - - 422 3,587
Leverage (Debt/EBITDA) 0.3393 x - 1.39 x 0.6515 x 0.593 x 0.3063 x - -
Free Cash Flow 1 2,034 1,837 2,228 2,207 3,453 2,534 2,870 3,200
ROE (net income / shareholders' equity) 28.3% 152% - 39,497% 473% 206% 123% 83.2%
ROA (Net income/ Total Assets) 2.23% 3.93% 3.03% 2.98% 2.93% 3.54% 3.75% 3.87%
Assets 1 38,421 -86,793 50,806 56,949 59,560 56,778 62,024 66,529
Book Value Per Share 2 13.90 -4.990 1.070 0.3400 - 7.890 15.00 24.50
Cash Flow per Share 2 11.10 10.80 12.80 12.80 19.10 17.60 23.30 25.30
Capex 1 310 370 438 496 458 483 529 559
Capex / Sales 0.17% 0.19% 0.2% 0.21% 0.17% 0.17% 0.17% 0.17%
Announcement Date 11/7/19 11/5/20 11/4/21 11/3/22 11/2/23 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Cencora, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
226.6 USD
Average target price
255.3 USD
Spread / Average Target
+12.70%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
CENCORA, INC. Stock Cencora, Inc.
+10.32% 44.62B
ABBOTT LABORATORIES Stock Abbott Laboratories
-7.16% 178B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-4.86% 67.04B
DEXCOM, INC. Stock DexCom, Inc.
-4.28% 47.24B
HOYA CORPORATION Stock Hoya Corporation
+8.14% 42.5B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+15.76% 29.99B
TERUMO CORPORATION Stock Terumo Corporation
+15.53% 25.22B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-5.88% 24.14B
ZIMMER BIOMET HOLDINGS, INC. Stock Zimmer Biomet Holdings, Inc.
-5.38% 23.69B
STERIS PLC Stock STERIS plc
+1.38% 22.04B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. COR Stock
  4. Financials Cencora, Inc.